Please login to the form below
Henrik Stenqvist joins Recipharm
Was previously CFO for Meda Group
Recipharm appoints Henrik Stenqvist as its new executive VP and chief financial officer, bringing 24 years of finance and management experience.
He said: “I’m looking forward to contributing to the continued success of Recipharm in my new capacity as chief financial officer of this leading company.”
Prior to joining Recipharm, Stenqvist served as CFO for Meda Group and has held other finance positions in the pharmaceutical industry.
Thomas Eldered, CEO of Recipharm, said: “I am very pleased to welcome Henrik, his extensive experience and perspectives in finance, business and strategic development in the pharmaceutical industry make him a great fit for Recipharm as we continue on our strong growth path.”
Stenqvist will be based at the company’s headquarters in Stockholm, Sweden where he will focus on financial planning and reporting.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
